Inside the Tirzepatide Supply Number That Could Bring The FDA Lawsuit Crashing Down

There is a moment buried in the April 24 court transcript that deserves much more attention.

At the heart of the lawsuit over compounded tirzepatide lies a simple but explosive discrepancy. The FDA removed tirzepatide from the drug shortage list based on a supply figure provided by Eli Lilly. That figure was used to justify cutting off access to compounded versions of the drug, effectively handing full market control back to Lilly.

But here is the problem…